Skip to content
value.today

Cytosorbents Corp is listed today as Cytosorbents Corporation: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cytosorbents Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2013$1 MPrivate placement after listingUnder $2 million

Cytosorbents Corp: Private sale, Jun 2013

Investors in this round

24 investors had bought by the notice of Aug 5, 2013: 23 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cytosorbents Corp as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$41,510
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Kathleen P. Bloch · Executive Officer
  • Phillip Chan · Executive Officer, Director · President, Chief Executive Officer and Director
  • Vincent P. Capponi · Executive Officer · Chief Financial Officer
  • Al P. Kraus · Director
  • Edward P. Jones · Director
  • James P. Gunton · Director
  • Joseph P. Rubin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Walter Greenblatt & Associates LLC (CRD 129291) · Princeton, New JerseySold in CT, GA, MA, ME, NJ, NY, PA

Remarks in the notice

  • On fees: “Walter Greenblatt and Associates LLC received a commission for funds they directly raised which was a total of $593,000 all from accredited investors”

Signed by Phillip Chan, President, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Aug 5, 2013. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Cytosorbents Corporation, its revenue in fiscal 2025 came from these business segments: Single reportable segment $37.06 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Cytosorbents Corp had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Aug 2013).

    SEC Form D (revenue range) · Aug 2013

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Aug 2013

Products and services#

No products or services of Cytosorbents Corp are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Cytosorbents Corp
InvestorKindAmountRoundRoleSource
Njtc Investment Fund, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Cytosorbents Corporation shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cytosorbents Corp
NameRoleNamed in
Kathleen P. BlochExecutive officerAug 2013
Phillip ChanPresident, Chief Executive Officer and DirectorAug 2013
Vincent P. CapponiChief Financial OfficerAug 2013
Al P. KrausDirectorAug 2013
Edward P. JonesDirectorAug 2013
James P. GuntonDirectorAug 2013
Joseph P. RubinDirectorAug 2013
Phillip ChanPresident, Chief Executive Officer and DirectorAug 2013

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.